Tag: Penumbra

Incuvate Files Patent Infringement Lawsuit Against Penumbra

Financial by 0 comments

Complaint alleges Penumbra’s THUNDERBOLT™ system infringes five Incuvate patents covering blood-clot detection technologyIRVINE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) — Incuvate, LLC today announced that it has filed a patent-infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California. The lawsuit, filed August 19, 2026, alleges that Penumbra’s recently launched THUNDERBOLT™ Neurovascular Thrombectomy System and related components infringe five Incuvate patents directed to real-time aspiration monitoring technology used in catheter-based thrombectomy procedures. Incuvate’s patents cover technology that uses pressure sensors, microprocessors, and pre-set pressure thresholds or differentials to provide real-time visual and audible feedback during aspiration procedures. Incuvate alleges that this technology helps distinguish between clot engagement and blood flow and provides clinicians with valuable information during thrombectomy procedures. The complaint identifies Penumbra’s THUNDERBOLT system, Penumbra ENGINE vacuum source, THUNDERBOLT tubing and module, and associated RED Reperfusion Catheters as accused products. Incuvate alleges that these products use patented technology to detect flow conditions, including the presence of clot, and provide users with feedback regarding flow status. Through this lawsuit, Incuvate seeks to hold Penumbra accountable for what Incuvate alleges is Penumbra’s unauthorized and willful infringement of the technologies embodied in the asserted patents. Incuvate is seeking damages, injunctive relief, and other remedies described in the complaint. A copy of the complaint is available through PACER Monitor in Incuvate, LLC v. Penumbra, Inc., Case No. 4:26-cv-08658. About IncuvateIncuvate works with medical device entrepreneurs to develop early-stage concepts into innovative products and leads them to market via new companies it finances, builds, and manages. Learn more at incuvatellc.com Media ContactLance CapelDirector of Strategy & External Relationslancemcapel@gmail.com

Continue Reading →

First Patient Enrolled in Penumbra’s FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

Neuro Uncategorized by 0 comments

ALAMEDA, Calif., July 7, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical…

Continue Reading →

New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients

Coronary/Structural Heart by 0 comments

ALAMEDA, Calif., April 13, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation achieved greater functional improvement, including walking significantly further and […]

Continue Reading →

Boston Scientific announces agreement to acquire Penumbra, Inc.

Financial by 0 comments

Acquisition to expand Boston Scientific’s cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., […]

Continue Reading →

Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism

Peripheral/Endo by 0 comments

–The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation    –Results of STORM-PE demonstrating superior efficacy of […]

Continue Reading →

Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism

Coronary/Structural Heart by 0 comments

ALAMEDA, Calif. – Oct. 27, 2025 – Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVT™), with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in […]

Continue Reading →

Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025

Financial by 0 comments

ALAMEDA, Calif., Oct. 8, 2025 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM Eastern Time at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) Conference….

Continue Reading →
1 2 3 … 7